GlassScriptPhysician profile
Joseph P Zingrone
NPI 1619923109
$1,787.19
in general payments reported to CMS, 2019-2025
26 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $130 · 2021: $473 · 2022: $413 · 2023: $262 · 2024: $252 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.82 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $261.43 | 2019-2021 | |
| Vifor Pharma, INC. | $229.74 | 2021-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $206.78 | 2020-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $181.62 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $173.06 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $96.65 | 2019-2024 | Jynarque |
| Glaxosmithkline, LLC. | $75.26 | 2022-2023 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $68.19 | 2021-2024 | Vafseo |
| Ardelyx, INC. | $65.87 | 2024-2025 | Ibsrela |
| Nevro Corp. | $49.63 | 2023 | Senza |
| Aurinia Pharma U.S., INC. | $48.39 | 2023-2024 | Lupkynis |
| Nxstage Medical, INC. | $38.08 | 2024 | |
| Amgen INC. | $36.08 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $34.36 | 2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $31.26 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.63 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $26.33 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2024 | Jardiance |
| Ascendis Pharma Endocrinology INC | $18.19 | 2025 | Yorvipath |
| Genzyme Corporation | $15.83 | 2022 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.69 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.45 | 2023 | |
| Alnylam Pharmaceuticals INC. | $14.40 | 2022 | |
| Travere Therapeutics, INC. | $13.73 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Zingrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.